2-氯-4-(三氟甲基)嘧啶-5-羧酸苄酯 | 175137-29-8

• 物质功能分类: 医药中间体 - 杂环化合物 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-氯-4-(三氟甲基)嘧啶-5-羧酸苄酯
• 中文别名: 苄基2-氯-4-三氟甲基嘧啶-5-羧酸盐
• 英文名称: benzyl 2-chloro-4-trifluoromethylpyrimidine-5-carboxylate
• 英文别名: 2-chloro4-trifluoromethyl-5-pyrimidine carboxylic acid benzyl ester；Benzyl 2-chloro-4-(trifluoromethyl)pyrimidine-5-carboxylate
• CAS: 175137-29-8
• 化学式: C₁₃H₈ClF₃N₂O₂
• mdl: MFCD00068148
• 分子量: 316.667
• InChiKey: RJHJVPJLOZDZSJ-UHFFFAOYSA-N

物化性质

• 熔点：
  45 °C
• 沸点：
  437.7±45.0 °C(Predicted)
• 密度：
  1.439±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.153
• 拓扑面积：
  52.1
• 氢给体数：
  0
• 氢受体数：
  7

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S24/25
• 危险类别码：
  R36/37/38
• 海关编码：
  2933599090

反应信息

• 作为反应物：
  描述：

  2-氯-4-(三氟甲基)嘧啶-5-羧酸苄酯 在 氢氧化钾 作用下， 以 1,4-二氧六环 、 乙醇 为溶剂， 生成 2-(phenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid
  参考文献：
  名称：

  Discovery of 2-[(2,4-Dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a Selective CB2 Receptor Agonist for the Treatment of Inflammatory Pain

  摘要：

  Selective CB2 receptor agonists are promising potential therapeutic agents for the treatment of inflammatory and neuropathic pain. A focused screen identified a pyrimidine ester as a partial agonist at the CB2 receptor with micromolar potency. Subsequent lead optimization identified 35, GW842166X, as the optimal compound in the series. 35 has an oral ED50 of 0.1 mg/kg in the rat FCA model of inflammatory pain and was selected as a clinical candidate for this indication.

  DOI：

  10.1021/jm061195+

文献信息

• [EN] COMBINATION OF CB2 MODULATORS AND PDE4 INHIBITORS FOR USE IN MEDICINE<br/>[FR] COMBINAISON DE MODULATEURS DU CB2 ET D'INHIBITEURS DE LA PDE4 UTILISEE EN MEDECINE
  申请人：GLAXO GROUP LTD

  公开号：WO2005074939A1

  公开（公告）日：2005-08-18

  Combination of one or more CB2 modulators such as a compound of formula (I), (II) and (III); and one more PDE4 inhibitors are useful of treating conditions which are mediated by the activity of CB2 receptors or conditions which are mediated by PDE4, such as an immune disorder, an inflamatory disorder, pain, rheumatoid.

  一种或多种CB2调节剂的组合，例如式(I)、(II)和(III)的化合物；以及一种或多种PDE4抑制剂对于治疗由CB2受体活性介导的疾病或由PDE4介导的疾病，如免疫紊乱、炎症性疾病、疼痛、类风湿等症状是有用的。
• N-alkanoylphenylalanine derivatives
  申请人：Hoffmann-La Roche Inc.

  公开号：US06455550B1

  公开（公告）日：2002-09-24

  Compounds of the formula: are disclosed which have activity as inhibitors of binding between VCAM-1 and cells expressing VLA-4. Such compounds are useful for treating diseases whose symptoms and/or damage are related to the binding of VCAM-1 to cells expressing VLA-4.

  揭示了具有以下化学式的化合物，这些化合物具有作为VCAM-1和表达VLA-4的细胞之间结合抑制剂的活性。这些化合物对于治疗那些症状和/或损害与VCAM-1与表达VLA-4的细胞结合有关的疾病是有用的。
• [EN] PYRIMIDINE DERIVATIVES AND THEIR USE AS CB2 MODULATORS<br/>[FR] DERIVES DE PYRIMIDINE ET LEUR UTILISATION EN TANT QUE MODULATEURS CB2
  申请人：GLAXO GROUP LTD

  公开号：WO2004018433A1

  公开（公告）日：2004-03-04

  This relates to novel pyrimidine derivatives, pharmaceutical compositions containing these compounds and their use in the treatment of diseases, particularly pain, which diseases are caused directly or indirectly by an increase or decrease in activity of the cannabinoid receptor.

  这涉及到新型嘧啶衍生物，含有这些化合物的制药组合物，以及它们在治疗疾病中的应用，特别是疼痛，这些疾病直接或间接地由大麻素受体活性的增加或减少引起。
• [EN] PYRIMIDINE COMPOUNDS<br/>[FR] COMPOSES DE PYRIMIDINE
  申请人：GLAXO GROUP LTD

  公开号：WO2004018434A1

  公开（公告）日：2004-03-04

  The present invention relates to novel pyrimidine derivatives, pharmaceutical compositions containing these compounds and their use in the treatment of diseases, particularly pain, which diseases are caused directly or indirectly by an increase or decrease in activity of the cannabinoid receptor.

  本发明涉及新型嘧啶衍生物、含有这些化合物的药物组合物以及它们在治疗疾病中的应用，尤其是治疗由于大麻素受体活性的增加或减少而直接或间接引起的疼痛等疾病。
• N-alkanoylphenylalamine derivatives
  申请人：——

  公开号：US20030109459A1

  公开（公告）日：2003-06-12

  Compounds of the formula: 1 are disclosed which have activity as inhibitors of binding between VCAM-1 and cells expressing VLA-4. Such compounds are useful for treating diseases whose symptoms and/or damage are related to the binding of VCAM-1 to cells expressing VLA-4.

  本文披露了一种化合物，其化学式为1，具有抑制VCAM-1与表达VLA-4的细胞结合的活性。这些化合物可用于治疗症状和/或损伤与VCAM-1与表达VLA-4的细胞结合有关的疾病。